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Abbreviations 
3F   three finger neurotoxin protein 
i-TA nickel nitroloacetic acid 
PCR Polymerase Chain Reaction 
PBS Phosphate Buffered Saline 
SDS-PAGE sodium dodecyl sulfate polyacrylamide  
gel electrophoresis 
EMCS -(6-maleimidocaproyloxy) succinimide 
SPR Surface Plasmon Resonance 
Kd dissociation constants 
EC50 term half maximal effective concentration 
IVC in vitro compartmentalization 
BDF the growth factor brain-derived  
neurotrophic factor 
TrkB tropomyosin-related kinase receptor type B 
MGSA/CXCL1 melanoma growth stimulatory activity factor 
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Chapter I 
Preface 
Antibodies, as a class of biological drugs, are most expected as one of the effective 
therapeutic tools against various diseases. They constitute the most rapidly growing 
class of human therapeutics and the second largest class of drugs after vaccines. 
However, it has become obvious that antibodies suffer from some fundamental 
disadvantages with increasing application in research, biotechnology, and medical 
therapy. For example, Immunoglobulins (Igs) are rather large molecules, thus limiting 
tissue penetration. Moreover, it costs a lot in commercial basis for antibody 
production, and not always successful. In the last decade, a minimizing antibody by 
rearranging antibody fragments has been developed to overcome the problems. 
Recently, various kinds of protein scaffolds derived from non-immunoglobulin 
proteins have also been shown to be useful as alternatives of antibodies. In particular, 
these proteins are smaller than Igs offering advantages in production and clinical 
effectiveness. Directed evolution has become a very popular strategy for improving or 
altering the biophysical properties of proteins, and generating proteins with novel 
functions. Disulfide-containing scaffolds, such as serine protease inhibitor (EETI-II, 
knottin family), bovine pancreatic trypsin inhibitor (BPTI; Kunitz domain), α-amylase 
inhibitor (tendamistat) and related proteins recently are popular targets of directed 
molecular evolution. Attention has been paid to their nature as small, defined 
structures and remarkably stable proteins. These scaffolds are considered to be able to 
present surface loops of varying sequence and length, including exposed hydrophobic 
residues. The property make scaffolds excellent candidates for novel binding 
specificities generating without significant changes in the structural framework. These 
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candidates have been successfully engineered for various purposes, such as for 
generating protease inhibitors, and ligands for macromolecules such as receptors. 
The first part of my study is functional characterization of trypsin protease 
inhibitors identified from a three-finger (3F) DNA library. The 3F scaffold used in 
this study is a novel snake α-neurotoxin, MicTx3, isolated from the South American 
coral snake, Micrurus corallinus. Due to their properties as small size, remarkably 
high temperature stability, resistence to proteases and low immunogenicity, 3F 
neurotoxins have broad spectrum in target molecules in nature, such as ion channels, 
receptors, proteases, etc. In the previous work, Naimuddin et al. prepared 3F random 
cDNA library based on the MicTx3 neurotoxin as a template and succeed to generate 
regulatory molecules against interleukin-6 receptor (IL-6R), and also achieved size 
reduction of 3F which can be conveniently prepared by chemical synthesis. Here, 
trypsin was chosen as target molecule to obtain protease inhibitors from the same 
library. Trypsin is a serine protease, which is used for numerous biotechnology 
processes in a range of laboratory tests because of its ability to hydrolyze proteins. 
These procedures include cell culture, separating tissues into constituent cells, sample 
preparation for genetic analysis, and protein studies. Clinical beneficial activities of 
trypsin inhibitors with therapeutic actions have been extensively investigated in acute 
pancreatitis, acute migraine, ischemic, cancers and so on. However, inhibitors also 
have some potentially adverse effects in special circumstances. I demonstrated the 
potential of the 3F scaffold in generating novel molecules for trypsin inhibitors by in 
vitro evolution using cDNA display. 
In second part of my study, In vitro compartmentalization (IVC) offers an 
alternative strategy based on partitioning reactions in water droplets dispersed to form 
microscopic compartments in water-in-oil emulsions. Because of the small size of 
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compartments, very large protein libraries (10
8
–10
12
 variants) can be expressed, and  
sequence variants with altered functions can be captured by a variety of selections. 
Previous study reported that a number of variants of the basic IVC selection method 
have been used for the identification of affinity reagents. The growth factor brain-
derived neurotrophic factor (BDNF) and its receptor TrkB mediate influence neuronal 
activity, function and survival throughout life. BDNF shows therapeutic potential in 
the treatment of various neurodegenerative diseases, such as Parkinson disease (PD), 
Alzheimer disease (AD) and amyotrophic lateral sclerosis (ALS). However, the 
therapeutic application of BDNF has been greatly limited because of its poor 
permeability blood-brain barrier (BBB). In order to generate small BDNF mimicking 
peptides, I prepared CXC scaffold random library based on CXCL1 to obtain specific 
ligand to target receptor TrkB by IVC selection. CXCL1 was chosen as template due 
to its small size (8 kDa), 2 disulfide bonds of four cysteine residues in conserved, and 
functions in biological processes of angiogenesis, inflammation, wound healing and 
tumorigenesis. I expect to produce CXC-based peptide probes to study the molecular 
mechanisms of neuronal development. Further study on generating small peptides 
targeting to TrkB receptor with potent neurotrophic activities, which may be of 
potential application in the treatment of various neurodegenerative diseases, is under 
progress. 
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Chapter II 
Directed evolution of three-finger toxin to produce serine protease 
inhibitors 
1. Abstract 
Directed evolution has become a very popular strategy for improving biophysical 
properties and even for generating proteins with novel functions. Recent advances in 
combinatorial protein engineering mean it is now possible to develop protein 
scaffolds that could substitute for whole antibody-associated properties as emerging 
therapeutic proteins. Protein, RNA, and DNA are the major targets of directed 
molecular evolution. In particular, disulfide-rich proteins are attractive templates for 
directed evolution in the search for novel molecules because they can regulate the 
activities of receptors, enzymes, and other molecules. Previous work from our group 
demonstrated that functional regulatory molecules against interleukin-6 receptor (IL-
6R) could be obtained by directed evolution of the three-finger toxin (3F) scaffold. In 
the present study, trypsin was selected as a target for directed evolution to further 
explore the potential use of the 3F cDNA display library. After seven rounds of 
selection, the DNA sequences converged. The recombinant proteins produced by the 
selected candidates had inhibitory activity against trypsin (Ki of 33–450 nM). Three 
out of six groups had Ki values that were comparable to bovine pancreatic trypsin 
inhibitor and soybean trypsin inhibitor. Two of the candidates also had inhibitory 
effects against chymotrypsin and kallikrein. This study suggests that 3F protein is 
suitable for the preparation of high-diversity libraries that can be utilized to obtain 
protease inhibitors. In addition to previous successful targeting of IL-6R, the 
technique developed in previous and present studies may have wide applications in 
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the generation of regulatory molecules for targets of interest, such as receptors, 
enzymes for research, diagnostic applications, and therapeutic uses. 
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2. Introduction  
Antibody-based medicine is expected to be one of the most effective novel 
therapeutic tools for combating various diseases, because this approach involves 
direct and specific interactions with disease-related molecules (1, 2). However, 
antibody production is not always successful and it may incur vast costs on a 
commercial scale (3). In the last two decades, approaches have been developed to 
overcome these problems, which involve minimizing antibodies by rearranging their 
fragments. Recently, various types of protein scaffolds derived from non-
immunoglobulin (non-Ig) proteins have also been shown to be useful alternatives to 
antibodies (4, 5). In particular, these proteins are smaller than immunoglobulin (Ig), 
which is advantageous in terms of production and clinical effectiveness. These 
proteins present surface loops with variable sequences and lengths, including exposed 
hydrophobic residues, but without significant changes in the structural framework (6). 
Disulfide-containing scaffolds, such as α-amylase inhibitor (tendamistat), bovine 
pancreatic trypsin inhibitor (BPTI; Kunitz domain), and serine protease inhibitor 
(EETI-II, knottin family), have been utilized as templates for different purposes to 
generate protease inhibitors (7, 8) and ligands for receptors (9). Previously, we 
utilized the three-finger toxin (3F) scaffold to prepare a cDNA library and we 
successfully generated regulatory molecules (antagonist and agonist) with activity 
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against the interleukin-6 receptor (IL-6R) (10). These proteins are 30–40 times 
smaller than Igs and the scaffolds are stabilized by disulfide bonds (11). The 3F 
scaffold used in this study is a novel snake α-neurotoxin, MicTx3, isolated from the 
South American coral snake Micrurus corallines. 3F protein families are found in a 
variety of organisms such as the elapidae snake and mammals, including humans (12), 
knotted together by 4-5 disulfide bridges. 3F proteins exhibit high temperature 
stability, resistance to proteases and low immunogenicity (13). 3F families are 
attractive because of their small size (7–8 kDa), β-structure(s), and the conservation 
of cysteine frameworks with several loops (the variable domain, which corresponds to 
the 3F structure). By exploiting the structural features of 3F toxins, new ligands for G 
protein-coupled receptors (GPCRs) with novel functions were generated by loop 
grafting 3F muscarinic toxins (14). The strict conservation of the cysteine frameworks 
and the high sequence diversity in the loops may allow the production of 3F proteins 
with a broad spectrum of target molecules, such as ion channels, receptors, and 
enzymes (15), and potentially allow 3F proteins to serve as excellent scaffolds for 
directed evolution. The specificity of 3F proteins for their respective receptors, which 
is conferred by the residues on the tips of the loops, has been investigated extensively 
(16, 17). In the present study, trypsin was used as the target molecule to obtain 
protease inhibitors from the 3F cDNA display library. Trypsin is a serine protease, 
12 
 
which is found in the digestive system of many vertebrates where it hydrolyses 
proteins. Trypsin is produced in the pancreas as the inactive proenzyme trypsinogen 
(18). Trypsin inhibitors reduce the availability of biologically active trypsin to cells or 
proteins and are important for research, diagnostics, and therapeutics (19, 20). The 
clinically beneficial activities of trypsin inhibitors with therapeutic effects have been 
investigated extensively in serious acute pancreatitis, migraine, ischemia, cancers, and 
other diseases (21-23). Aprotinin, or BPTI, is known to inhibit plasmin, and has been 
used for clinical purposes to reduce blood loss during heart and liver surgery (24). 
However, trypsin inhibitors also have potentially adverse effects in specific 
circumstances (25, 26). For example, the use of BPTI in diabetic patients may be 
related to an increased risk of renal dysfunction. Acetylcholinesterase inhibitors have 
been isolated from 3F toxins, i.e., faciculins, but trypsin inhibitors have not been 
reported from 3F toxins. The present study demonstrates the potential use of the 3F 
scaffold for generating novel molecules that act as serine protease inhibitors via the 
directed evolution of a cDNA display library.  
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3. Materials and methods  
3.1   Preparation of the 3F library and target protein selection  
The full method for the construction of the three-finger (3F) protein library, cDNA 
display and selection of target protein were described previously by Dr. Mohammed 
Naimuddin (10). 
3.1.1   Construction of the 3F library  
Briefly, MicTx3 cDNA was used as a template and the 3F cDNA library was 
constructed by introducing (NNS)s into each finger tip [Residues T5–P10 in loop 1 
(six residues), K25–V34 in loop 2 (ten residues), and A46–H52 in loop 3 (seven 
residues)] (Fig. 3A). The 3F genetic construct (Fig. 1C) was prepared by joining the 
fragments by overlap PCR to facilitate the formation and purification of cDNA 
displayed proteins. Briefly to the sequence of the 3F library, SP6 fragment containing 
the SP6 promoter, cap site, Xenopus globin untranslated sequence (UTR) and 
translation initiation site was added at the 5’ end, while the (G3-S) spacer, C-terminal 
6xHis, (G3-S) spacer and Y-tag sequences were added at the 3’ end. The final library 
was expressed and purified by Ni-NTA resin (Qiagen, CA, USA) and the quality of 
the library was assessed by sequencing 20 randomly selected clones after cloning 
them into the TA cloning vector (Invitrogen, CA, USA). 
3.1.2   Transcription of DA library  
The DNA library was subjected to urea polyacrylamide gel electrophoresis (PAGE), 
purified from the gel, annealed by heating at 94 °C, and gradient cooling to form the 
correctly paired double-stranded DNA. The DNA templates were transcribed using 
SP6 RNA polymerase with a RiboMAX Large Scale Production Systems (Promega, 
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WI, USA). The reactions were terminated by adding DNase I and the products were 
purified using the phenol/chloroform method. The RNA concentration was measured 
at 260 nm using a spectrophotometer. 
3.1.3   Synthesis of the puromycin-linker and ligation to mRA  
The puromycin-linker was synthesized as described previously (10), by cross-
linking two modified oligonucleotides with the hetero-bifunctional reagent, N-(6-
maleimidocaproyloxy) succinimide (EMCS). The modified oligonucleotides, Puro-F-
S [5’-(S)-TC (F)-(Spec18)-(Spec18)-(Spec18)-(Spec18)-CC-(Puro)-3’] and Biotin-
loop were custom synthesized (BEX Co, Tokyo, Japan). The mRNA was annealed to 
the biotinylated puromycin-linker DNA (1:1 ratio) via the Y-tag sequence in 1× ligase 
buffer (Takara, Kyoto, Japan) by heating at 94 °C and cooling slowly. The mRNA 
and linker were ligated via the addition of T4 kinase (3 units) and T4 RNA ligase (20 
units) (Takara) at 25 °C for 1 h, then the conjugated product was purified using an 
RNeasy Kit (Qiagen). The ligation efficiency and the purity of the products were 
checked by PAGE using FITC and/or Vistra Green (Molecular Probes, USA) staining 
with a fluoroimager (Bio-Rad, Hercules, CA, USA). 
3.1.4   cDA display  
The mRNA-puromycin linker DNA (3-5 picomoles) was translated in 25 µl using a 
Rectic Lysate IVT Kit (Ambion, Austin, TX, USA) at 30 °C for 10 min in the 
presence of protein disulfide isomerase (1:1 ratio of display protein/PDI) (27). After 
translation, the proteins were covalently linked to the puromycin-linker in the 
presence of 65 mM MgCl2 and 750 mM KCl at 37 °C for 2 h. The translation 
products conjugated with the corresponding mRNA were purified using oligo-dT. 
cDNA synthesis was followed by M-MLV reverse transcriptase (Takara) priming 
from the ‘built-in’ primer included in the linker. After the displayed proteins were 
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released by restriction digestion with PvuII, the full-length displayed proteins were 
purified via the C-terminal 6×His-tag using Ni-NTA resin (Qiagen). The overall 
process was scaled up for library preparation where 200 picomoles were used for 
translation. The subsequent rounds (R) were reduced to 1/5th for R2–R5 and 1/10th 
for R6–R7. 
3.1.5 Preparation of immobilized enzymes 
Porcine pancreas trypsin (Sigma–Aldrich, Saint Louis, USA) were immobilized on 
NHS-activated Sepharose 4 Fast Flow (GE Healthcare, Milwaukee, UK) by utilizing 
the amine coupling chemistries to form a chemically stable amide bond, according to 
the manufacturer’s instructions. The coupling efficiency was estimated from the 
absorbance measurements of the initial and unbound protein at 280 nm. The activity 
of the immobilized enzyme was measured using an activity assay (see below, 
“Protease inhibition activity assay”). Non-coated beads were also prepared using the 
same derivatization procedure, but in the absence of the enzyme. 
3.1.6 Selection of target protein (trypsin) binders  
The 3F library was screened to identify molecules that bound trypsin selectively. 
Each round of selection was performed using non-coated beads and trypsin-coated 
beads in a batch-selection process with phosphate-buffered saline (PBS), which 
contained an additional 100 mM NaCl and 0.1% Tween-20. The initial round 
contained 2 nM cDNA displayed protein and 300 nM trypsin. Before selecting the 
trypsin binders, non-specific Sepharose binders were excluded by preincubating the 
library with non-coated beads for 1 h. This was followed by incubation of the 
precleared library with trypsin-coated beads for 1 h. After incubation, the trypsin 
beads were washed several times with the PBS/NaCl/Tween-20 buffer and eluted 
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using the same buffer containing 100 mM dithiothreitol (Sigma). The eluted products 
were desalted and PCR amplified (denaturation for 20 s at 94 °C, annealing for 15 s at 
60 °C, and extension for 30 s at 72 °C) with forward and reverse PCR primers, 
purified, and used as templates for PCR amplification with the SP6 fragment. The 
DNA products were gel-purified, transcribed, mRNA-ligated to the puromycin-linker, 
translated, transformed into display proteins, reverse transcribed, Ni-NTA affinity-
purified, quantified, and used in the next round of selection. The trypsin concentration 
and the incubation period were reduced gradually, whereas the number of washes was 
increased progressively during further rounds of selection to apply selection pressure. 
After seven rounds of stringent selection, the DNA pool was amplified using primers 
that encoded the initiation methionine region and the C-terminal region. The PCR 
products were cloned into the vector pCR2.1-TOPO using a TOPO TA cloning kit 
and transformed into electrocompetent cells, TOP10. Positive clones with the correct 
insert size were sequenced (Operon Biotechnologies, Tokyo, Japan). 
3.1.7 Assessment of the selection 
Direct binding analysis using displayed proteins: Selected Round 7 library (R7) 
was prepared by the cDNA display method and purified by spin columns (Bio-Rad). 
One of the fractions was denatured by treatment with 100 mM dithiothreitol (DTT) 
for 1 h and purified (designated as R7-D). Purified display proteins (R7 and R7-D; 5 
µl) were mixed with non-coated beads and 250 nM of trypsin coated beads in PBS-
BSA (0.01% BSA) and incubated at 25 °C for 1 h. The mixtures were washed with 
PBS-T (0.1% Tween) and subsequently incubated with Penta.His-HRP (Qiagen) in 
PBS-T for 30 min. at 25 °C. The mixtures were then washed several times with PBST 
followed by addition of the substrate, 3, 3’, 5, 5’-tetramethylbenzidine (TMB; Sigma). 
After color development was complete, the reaction was stopped by the addition of 
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H2SO4, the sample was centrifuged, and absorbance measured at 450 nm.  
3.2 Preparation of selected candidate proteins 
The recombinant proteins were prepared using a pBAD/TOPO ThioFusion 
Expression Kit (Invitrogen), as described by Naimuddin et al. (10) with several 
modifications. The selected candidate clones were PCR amplified using primers 
encoding the N-terminal methionine and C-terminal 6×His, before being subcloned 
into the vector pBAD/Thio-TOPO and transformed. Clones with the correct 
orientation were cultured overnight at 37 °C in Luria-Bertani (LB) medium containing 
50 µg/ml ampicillin. A small portion of the culture was transferred to fresh LB-
ampicillin medium and grown to an OD600 of 0.5 at 37 °C, then induced with 0.02% 
arabinose for 4 h at 37 °C. The cells were pelleted by centrifugation at 3000 rpm for 
20 min at 4 °C and resuspended with Bugbuster Protein Extraction Reagent (Novagen, 
San Diego, USA) in the presence of 25 U/ml Benzonase, 1000 U/ml rLysozyme, and 
protease inhibitor cocktail (Sigma) at 25 °C for 30 min. The lysate was centrifuged, 
separated into the supernatant (soluble fraction) and the pellet (insoluble fraction), and 
analyzed by Tris-glycine sodium dodecyl sulfate-PAGE (SDS-PAGE). Four of the 
candidate proteins were expressed mainly as soluble proteins, whereas the other two 
proteins were expressed as insoluble forms in inclusion bodies. The insoluble forms 
of the proteins were recovered from the inclusion bodies using a solubilizer (50 mM 
CAPS, pH 11.0, 0.3% N-lauroylsarcosine and 1 mM dithiothreitol), and refolded with 
a Protein Refolding Kit (Novagen), according to the supplier’s protocol. The soluble 
and refolded proteins were purified using TALON metal affinity resin (Clontech, 
Canada, USA), which had an affinity for the 6×His-tag of the expressed proteins 
under native conditions, according to the manufacturer’s instructions. The buffers 
were exchanged with PD-10 desalting columns in the following protease assay. The 
18 
 
proteins were also confirmed by Western blotting for 6×His using a HRP conjugated 
anti Penta-His antibody (Qiagen). The concentrations were measured using a BCA 
Protein Assay Kit (Takara) at 595 nm with bovine serum albumin (BSA) as the 
standard, and based on densitometry measurements of the protein bands on SDS-
PAGE gels using known protein concentration standards, such as BSA. Thioredoxin 
(Trx) derived from the vector pBAD/Thio-TOPO was prepared and used as a negative 
control in the experiments. 
3.3  Binding activity against trypsin 
Dissociation constants (Kd) of candidate peptides were measured by Surface 
Plasmon Resonance (SPR) with a Biacore X (GE Healthcare) according to the 
manufacturer’s instructions. Bovine pancreas trypsin (Sigma) was immobilized on the 
surface of a CM5 sensor chip flow cell, in concentration of 50 µg/ml by the Biacore 
amine coupling kit (Biacore) according to the procedure suggested by Biacore. 
Candidate peptides and soybean trypsin inhibitor (STI; Wako Pure Chemical 
Industries, Osaka, Japan) were dissolved in HBS-EP buffer (0.01 M HEPES pH 7.4, 
0.15 M NaCl, 0.005% v/v Surfactant P20) to various concentrations (0-10 µM) and 
used as analytes. Candidate peptides and soybean trypsin inhibitor were injected over 
the trypsin surface or the blank surface. All the above experiments were run at RT, 
using HBS EP Buffer as running buffer. The trypsin surface was regenerated by two 
injections of 10 mM NaOH. The blank sensorgram was subtracted from each sample 
sensorgram and the binding response evaluated. The binding responses, were 
measured in the three set of experiments, were plotted to find out the relative 
potencies of aptamers in binding trypsin. Data were analyzed with the affinity 
analysis model in the BIA evaluation software. 
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3.4  Protease inhibition activity assay 
Protease assays were performed with the following pairs of enzyme and substrate: 
bovine pancreas trypsin (Sigma) and Bz-Arg-MCA (Peptide Institute, Osaka, Japan); 
bovine pancreas chymotrypsin (Sigma) and Suc-Ala-Ala-Pro-Phe-MCA (Peptide 
Institute); porcine pancreas kallikrein (Sigma) and Z-Phe-Arg-MCA (Peptide 
Institute), in 85 mM Tris–HCl (pH7.5) buffer containing 112.5 mM NaCl, 1.5% PEG 
6000, and 15 mM CaCl2. To compare the inhibitory activities, 100 nM BPTI (Santa 
Cruz Biotechnology, USA) was used. After incubating 50 nM trypsin with the 
candidate proteins for 30 min at 37 °C, the trypsin activities were measured by adding 
400 µM of the fluorogenic substrate Bz-Arg-MCA (28). The time-courses of the 
fluorescence changes were monitored using a Spectra MAX Gemini (Molecular 
Devices, Sunnyvale, CA) with excitation at 355 nm and emission at 460 nm (29). The 
data were analyzed and plotted using Origin 8 (OriginLab, Northampton, MA). The 
half-maximal effective concentration (EC50) values were estimated from plots of the 
percentage inhibition versus the inhibitor concentration. The apparent Kis (Ki
app
) was 
calculated using the equation: Ki
app
= EC50/[(1+S/Km)], where S represents the 
substrate concentration (30). The Km of trypsin for the substrate Bz-Arg-MCA was 
200 µM. The data were plotted and each data point represents the mean from a single 
experiment, which was performed in triplicate. In the data plots, the error bars 
represent the standard deviation based on three replicate reactions.  
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4. Results  
4.1 Selection of novel trypsin inhibitor candidates by directed evolution 
Proteins with trypsin inhibition activity were selected by directed evolution using 
cDNA display, as described previously (10). The selection procedure is illustrated in 
Fig. 2. The mRNA (genotype) and its protein (phenotype) were linked via puromycin, 
followed by rapid conversion of the mRNA to cDNA by reverse transcription, and 
specific in vitro protein labeling at the C-terminus. 
The selection procedures were repeated for seven rounds and the conditions were 
made progressively more stringent during this process. After seven rounds, the 
selected DNA pool was subcloned. Three-hundred transformants were randomly 
selected and the plasmid DNA products were sequenced. The fully translated protein 
sequences were classified into six groups based on variations in their predicted amino 
acid sequences (Fig. 3). Group 1 sequences comprised 20.6% of the total, followed by 
group 2 with 8.8%, group 3 with 5.1%, group 4 with 2.5%, and group 5 and group 6, 
each with 0.6%. Mutations were observed in the non-randomized portions, which may 
have been due to failed polymerase reactions in the 385 cycles (31). Point mutations 
and silent mutations (different coding sequences that encoded the same amino acid) 
were also observed in the loop sequences, which indicated that different amino acid 
residues may have been present in these regions. The group 1 sequence was almost 
the same as that of group 2, except that the mutations R9 (group 1) and Q9 (group 2) 
were present in random residues at the tip of loop1. Group 3 was almost the same as 
group 5, except that the mutations T52 (group 3) and K52 (group 5) were present in 
random residues at the tip of loop 3. The cysteine framework was intact in most of the 
clones. 
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4.2 Expression of candidate proteins 
The recombinant candidate proteins were expressed as thioredoxin and 6×His 
fusion proteins using the vector pBAD/Thio-TOPO. The expressed proteins from 
group 2, group 3, group 4, and group 5 were expressed mainly as soluble proteins, 
whereas the proteins from group 1 and group 6 were expressed as insoluble forms in 
inclusion bodies. The expressed proteins of groups 2-5 were purified using TALON 
metal affinity resin in native conditions. The insoluble forms of the group 1 and group 
6 proteins were recovered from the inclusion bodies with solubilization buffer, with a 
solubilizer, refolded in the presence of reduced and oxidized glutathione (a redox 
pair), and purified with TALON metal affinity resin. The proteins were analyzed by 
SDS-PAGE (Fig. 4) and Western blotting (data not shown). The purities were 70–
90% and the average yield of the recombinant proteins from bacterial culture was 0.7 
mg/100ml.  
4.3   Biochemical characterization of the recombinant proteins 
4.3.1   Inhibitory activities against trypsin 
First, the inhibitory activities of the candidates against trypsin were examined using 
in vitro biological assays. The recombinant proteins from group 1, group 2, group 5, 
and group 6 had effective dose-dependent inhibitory activities against trypsin, 
whereas the proteins in group 3 had lower activities and the proteins in group 4 had 
essentially no effects (Fig. 5). The EC50 and Ki
app 
(apparent inhibition constants) were 
estimated and are shown in Table 1. The effective inhibitory activity of proteins in 
group 1 was double that of those in group 2 (102 nM vs. 260 nM). The two candidate 
groups could be distinguished based on their different amino acid residues, i.e., R9 
(group 1) and Q9 (group 2). The effective inhibitory activity of proteins in group 5 
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was almost 15 times that of those in group 3 (66 nM vs. 900 nM), and these two 
candidate groups could be distinguished based on their different amino acid residues, 
i.e., T52 (group 3) and K52 (group 5). The inhibitory activities of selected proteins 
were also compared with those of Kunitz-type protease inhibitors, i.e., BPTI and STI. 
The Ki
app 
values of BPTI and STI were 25 nM and 29 nM, respectively. The inhibitory 
activities of the group 5 and the group 1 proteins against trypsin (33 nM and 51 nM, 
respectively) were comparable to those of BPTI and STI. To investigate the 
specificity of the inhibitory effects, the effects of the recombinant proteins from group 
1 and group 5 were tested using two other serine proteases, i.e., chymotrypsin and 
kallikrein (Fig. 6). The group 1 and group 5 proteins had dose-dependent inhibitory 
activities against kallikrein, where the Ki values of group 1 and group 5 were 50 nM 
and 29 nM, respectively. Group 5 had a more potent inhibitory activity against 
kallikrein than trypsin. The activity of chymotrypsin was suppressed by up to 80–85% 
using the group 1 (500 nM) and group 5 (100 nM) proteins. It was remarkable that the 
compensatory recovery of chymotrypsin activity occurred in a dose-dependent 
manner with higher concentrations of the proteins.  
4.3.2   Binding activities of candidate peptides    
Binding activities of candidate peptides were measured by Surface Plasmon 
Resonance (SPR). The amount of trypsin in concentration of 50 µg/ml immobilized 
on the CM5 sensor chip surface of the flow cell was 1709.6 RU. Tested aptamers, 
candidate proteins and STI were dissolved to various concentrations and used as 
analytes. Proteins group 1 at variable concentration 0.5, 1, 2, 4.5 and 9 µM, and group 
3 at 0.2, 2, 4, 8 and 16 µM  were performed, kinetic analysis gave dissociation 
constants (Kd) of 3.67 µM (group 1) and 7.39 µM (group 3). As positive control, 
trypsin inhibitor STI at 1, 10, 100 and 1000 nM were performed, kinetic analysis gave 
23 
 
a Kd of 20 nM (Data not shown). Previous report  shows the Kd for the interactions of 
STI-bovine pancreatic trypsin and BBI-bovine pancreatic trypsin were determined, 
respectively, to be 47.0 nM and 83.6 nM, which is comparable to the Kd of STI in our 
study. The binding activities values of our recombinant peptides data were about 100 
times lower than that of the Kunitz-type inhibitors.  
5. Discussion 
Antibodies are the most rapidly growing class of human therapeutic molecules and 
the second largest class of drugs after vaccines. Antibodies have undergone 
significant evolution since entering clinical application, with remarkable success. 
However, it is obvious that antibodies have several fundamental disadvantages, 
including their large size, steric hindrance restriction of their tissue penetration (solid 
tumors and poorly vascularized tissues), and planar binding interfaces, which raise 
doubts in their practical applications in research, biotechnology, and medical therapy. 
In the past two decades, over 50 different protein scaffolds (Ig-like scaffolds and non-
Ig-based scaffolds) have been developed and utilized to overcome some of these 
constraints. Protein scaffolds that serve as alternatives to whole antibodies have 
proved successful as therapeutic candidates with appropriate clinical efficacy (32, 33). 
Disulfide-containing scaffolds and related proteins have been utilized as templates to 
generate protease inhibitors and ligands for macromolecules. Previously, we 
successfully utilized the 3F scaffold to generate regulatory molecules (antagonist and 
agonist) against IL-6R (10). In the 3F-scaffold library, 23 accessible positions were 
randomized within the three exposed loops. 
Applications of trypsin inhibitors in therapeutic activities have been investigated 
extensively in acute pancreatitis, acute migraine, ischemia, cancers, and other diseases 
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(21). Although they have been demonstrated to be effective, these drugs have 
potentially adverse effects in special circumstances (25, 26). In the present study, the 
3F cDNA display library was preferentially screened by targeting trypsin. After 
selection by affinity to immobilized trypsin, selected candidate proteins were 
expressed as Trx fusion proteins and four exhibited effective inhibitory activities 
against trypsin. The inhibitory activities were in the nanomolar range, with Ki values 
ranging from 33 nM to 133 nM. In the present study, the Ki values were higher, but 
comparable to those reported previously for BPTI (25 nM) and STI (29 nM) (28). The 
effective inhibitory activity of the candidate proteins in group 1 was twice that of 
those in group 2. The two candidates could be distinguished based on their different 
amino acid residues, i.e., R9 (group 1) and Q9 (group 2). The effective inhibitory 
activity of the candidate proteins in group 5 was almost 15 times that of those in 
group 3, and the two candidates could be distinguished based on their different amino 
acid residues, i.e., T52 (group 3) and K52 (group 5). It is interesting to note that the 
presence of a basic amino acid residue Lys (K) at position 52 instead of Thr (T) in 
random residues at the tip of loop 3 may play an important role in determining the 
inhibitory activity against trypsin. This is because typical serine protease inhibitors 
bind to the reactive centers of proteases via positively charged amino acid residues 
(34). It has been reported that the Kunitz-type protease inhibitors BPTI and STI can 
inhibit chymotrypsin activity and the active site of STI is analogous with respect to 
trypsin and chymotrypsin (35). The investigation of the inhibitory activity of the 
candidates against chymotrypsin produced interesting results, where the candidate 
proteins in group 1 and group 5 had high inhibitory effects at low doses and low 
inhibitory effects at high doses. 
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Kallikrein belongs to the family of serine proteases and is structurally related to 
trypsin. Plasma kallikrein plays a major role in producing bradykinin, which is a 
vasodilator that increases vascular permeability, activates inflammation, and produces 
pain (36). The leading cause of morbidity and mortality in hereditary angioedema 
(HAE) patients is plasma kallikrein-mediated excessive production of bradykinin. 
This is the rationale for the development of potent inhibitors of kallikrein (37, 38). 
Plasma kallikrein inhibitors also have potential therapeutic uses in the treatment of 
sepsis and septic shock (39). The group 1 and group 5 recombinant proteins generated 
via the directed evolution of the 3F library were effective inhibitors of kallikrein with 
Ki values of 50 nM and 29 nM, respectively. The present study demonstrates that the 
3F protein library may provide a new platform for discovering potent small molecule 
inhibitor(s), where the effectiveness may be optimized to treat kallikrein-mediated 
inflammatory disorders while minimizing the adverse effects.  
Previously, we demonstrated that functional regulatory molecules with activity 
against IL-6R could be generated via the directed evolution of the 3F scaffold. The 
present study extended the application of this technique by targeting trypsin. Selected 
proteins had a broad range of inhibitory activities against trypsin and some also had 
inhibitory effects against other proteases. Some protein protease inhibitors have been 
reported to inhibit multiple proteases, such as trypsin and chymotrypsin (35), or 
trypsin and kallikrein (40), which are assumed to share a conserved molecular 
environment in the active pocket of the proteases. The advantage of our techniques is 
that additional conditions can be incorporated during the selection step to include 
(positive selection) and/or exclude (negative selection) binding proteins. In future 
studies, this technique could be used to generate inhibitors, which may facilitate the 
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strict discrimination of inhibitors of trypsin, kallikrein, and plasmin with broad 
applications in research, diagnostics, and therapeutic uses. 
6. Conclusions  
In the present study, selected candidate proteins with effective serine protease 
inhibition activities were generated via the directed evolution of a 3F library. This 
procedure was based on a high-diversity library where the 3F scaffold was utilized as 
a template and the tips of the loops were randomized. In addition to our previous 
success in targeting IL-6R, the technique described in the present study may have 
wide applications in the generation of regulatory molecules that target molecules of 
interest, such as receptors, as well as enzymes for research uses. Recent research has 
shown that various scaffolds may potentially be used as substitutes for whole 
antibodies and their associated properties have been validated, which has allowed 
them to be translated into biological agents with drug-like properties in clinical 
development. Thus, the 3F cDNA library, which can be used as a directed evolution 
template to target proteases and receptors, may be useful for generating viable drugs 
with diagnostic and therapeutic applications in a post-antibody landscape. 
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LVCYTNVLEPPGTLETCPDDFTCVKKWEGGGRRVTQYCSHACAIPASYEFVHCCQTDKCNG
loop 1                                           loop 2                                       loop 3
Loop 1 
Loop 2
Loop 3 
Fig. 1. Construction of the three-finger (3F) cDNA library 
(A) Primary structure (B) 3D structure of the 3F protein. The four disulfide bonds are formed 
between 8 conserved cysteines. The loops are shown in color and were randomized to generate 
the libraries. (C) Genetic construct adopt for cDNA display SP6 contains the sp6 promoter, 
capping site and Xenopus globin untranslated sequence (UTR). ATG is the translation initiation 
codon. The 3F gene with the three randomized loops provides the basis of the library. G3S is 
spacer, 6XHis facilitates affinity purification by Ni-NTA, and Y-tag facilitates ligation of mRNA 
to the puromycin linker which contains the complementary Y-tag sequence. 
A 
C 
aimuddin et al., 2011 
B 
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DNA library
Transcription
SA beads capture and
reverse transcription
Recovery of  binding molecules 
Selection of molecules for desired targets
Sequencing
Cell- free translation
PCR Amplification
Protein-Puromycin-DNA complex
Restriction enzyme 
digestion
mRNA
Ligation of  Puromycin linker
Biotin
Streptavidin (SA)
Immobilized target Puromycin
Ni-NTA resin capture
Fig. 2. Overview of the cDNA display method used for evolution in vitro.  
cDNA display was based on covalent fusion of the expressed protein (phenotype) and the 
encoding cDNA (genotype) via puromycin attached to an oligonucleotide linker. The library was 
prepared using the construct required for cDNA display, transcribed into mRNA, and ligated to 
the puromycin-linker. The mRNA-linker conjugates were translated in a cell-free translation 
system. After purification, the cDNA products were synthesized by reverse transcription and the 
full-length synthesized proteins were purified using Ni-NTA resin. After selecting the molecules 
using the immobilized targets, the bound molecules were recovered, purified, amplified, and 
employed in the next round of selection.  
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Wt LVCY TNVLEP PGTLETCPDDFTCV KKWEGGGRRV TQYCSHACAIP ASYEFVH CCQTDKCNG
XXXXXX    XXXXXXXXXX  XXXXXXX % population
LRVFRY    TTSPASEHTM PRKRQSP 20.6
LRVFQY    TTSPASEHTM PRKRQSP 8.8
APPVCD    ARKILSGCHS  KCHQLYT 5.1
APPVCD    ARKILSGCHS  KCHQLYK 0.6
MAVPRL    NGSDHTMSGS  SADNAGD 2.5
R0
Group 1
Group 2
Group 3
Group 5
Group 4
Group 6 LGPVGT    GRNRTLSPHH  PLATQRS 0.6
Fig. 3. Sequence alignment of the selected proteins with the template 3F protein, 
MicTx3.  The sequence of Mic Tx3 was used as the template for the 3F library, which is 
indicated by ‘wt,’ whereas the initial 3F library is indicated as ‘R0.’ The cysteine residues are 
shown in red. The conserved disulfide bonds in 3F proteins are indicated by black lines. 
Randomized sequences in the tips of loops are shown as underlined letters in ‘wt’ and are 
indicated by ‘X’ in ‘R0’. The sequences of the candidate clones were assigned to six groups 
based on their sequence identities. The same sequences of selected clones that appeared in the 
tips of different groups are shown in the same color. Mutations in the same color are indicated by 
the underlined residues. The E9 and H52 residues were found to be mutated to R (group 1)/Q 
(group 2) and T (group 3)/K (group 5) residues, respectively. The percentage population 
indicates the proportion of the selected molecules (300 clones) that were sequenced.  
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29 kDa
18.4 kDa
14.3 kDa
6.2 kDa
43 kDa
Fig. 4. Purification of the recombinant 3F candidate proteins.  
The selected candidate proteins were expressed as 6×His and thioredoxin (Trx) fusion proteins, 
and purified using TALON metal affinity resin. The elution buffer was replaced with PD-10 
desalting columns and the purified proteins were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, before staining with Coomassie Brilliant Blue R-250. Trx 
without candidate protein (molecular weight 13.1 kDa) was prepared as the negative control for 
the protease assay. The arrows indicate the bands with the expected size of purified candidate 
proteins (average molecular weight 21.5 kDa). The upper bands were approximately twice the 
size of the candidate proteins and they may have corresponded to dimers of the candidate 
proteins (average molecular weight 43.0 kDa). Some 3F proteins, including kappa-bungarotoxin 
and alpha-cardiotoxin, tend to form dimers in solution. The samples loaded in the respective 
lanes were as follows: molecular weight markers (lane 1); Trx (lane 2); group 1 (lane 3); group 3 
(lane 4); group 5 (lane 5); group 4 (lane 6); group 2 (lane 7); group 6 (lane 8).  
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Fig. 5. Dose-dependent inhibitory effects of the selected 3F proteins on trypsin. 
Trypsin (50 nM) was incubated with the indicated concentrations (from 0 nM to 5 µM) of 
candidate recombinant proteins (group 1 to group 6) for 30 min at 37 °C and the trypsin 
activities were measured using fluorogenic substrates. Thioredoxin was used as a negative 
control in the protease assay. The asymptotic value of the sigmoid curve was defined as the 0% 
trypsin activity. The 100% trypsin activity value was determined based on measurements in the 
absence of candidate protein. The broken line indicates the asymptotic value of the sigmoid 
curve. Each data point represents the mean from a single experiment, which was performed in 
triplicate. The error bars represent the standard deviation.  
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Fig. 6. Effects of the selected 3F proteins on serine proteases. 
Trypsin (50 nM), chymotrypsin (10 nM), and kallikrein (20 nM) were incubated with the 
indicated concentrations (0 nM, 500 nM, and 1 µM) of candidate and thioredoxin proteins for 30 
min at 37 °C. The protease activities were measured using fluorogenic substrates. Each data 
point represents the mean from a single experiment, which was performed in triplicate. The error 
bars represent the standard deviation.  
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Table 1. Comparison of the trypsin inhibition activities of selected 3F proteins 
 
 
 
a 
 EC50= the half-maximal effective inhibitory concentration 
b  
Ki = EC50/[(1+S/Km)]
 
c  
NI = non-inhibitory 
d  
Reference 28 
 
 
Protease 
 
Substrate 
 
Km (µM) 
 
EC50 
a
 (nM)  
 
Ki 
b
 (nM)  
 
3F proteins 
 
3F proteins 
 
BPTI    STI 
1            
 
2
 
3  
 
4 
 
5 
 
6  
 
1  
 
2  
 
3  
 
4 
 
5  
 
6  
Trypsin 
(bovine)       
 
Bz-Arg-MCA 
 
200 102 260 900 NI
c
 66 140 51 
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Chapter Ⅲ 
In vitro evolution of CXC-based peptides to study the 
molecular mechanisms of neuronal development 
Summary 
Directed evolution has now been applied to a wide range of protein functions, 
including ligand and protein binding, and regulatory functions in the past few years 
(41, 42). The cDNA display technology utilized a cell-free translation system was 
performed in second chapter to generate trypsin inhibitor from a 3F neurotoxin cDNA 
library. In this chapter, I employed an entirely different strategy based on in vitro 
compartmentalization (IVC) in emulsion. This strategy was used to physically link 
proteins (phenotype) to the DNA (genotype) that encodes them of reactions in the 
aqueous droplets of water-in-oil via microbeads (43, 44). In vitro 
compartmentalization (IVC) offers an alternative strategy dispersed to form 
microscopic compartments in water-in-oil emulsions based on partitioning reactions 
in water droplets (46, 47). Water-in-oil emulsions allow individual genes were 
transcribed and translated in femtoliter-sized aqueous reaction vessels (48, 49). Small 
size of the compartments, large protein libraries (10
8
–10
12
 variants) can be expressed, 
and sequence variants that lead to altered function can be captured by a variety of 
selections and screens (50). Previous study reported that a number of variants of the 
basic IVC selection method have been used for the identification of affinity reagents. 
For example, Sepp et al. demonstrated that genes encoding peptides bearing a FLAG 
tag could be enriched by co-immobilizing the genes and an anti-Flag antibody on a 
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microbead. Following translation, compartments were broken and bead-bound 
peptides were fluorescently-labeled and isolated by FACS (43, 51). Using a different 
approach, Yanagawa’s lab reported the affinity enrichment of peptide-SA 
(streptavidin) fusions and the biotinylated genes that encoded them. SA-fusions 
translated within a compartment associated tightly with their genes (52).  
Here, I expect to generate novel small peptides targeting to the growth factor brain-
derived neurotrophic factor (BDNF) receptor/TrkB from CXC-based random cDNA 
library by IVC selection in emulsion. Proteins are classified as chemokines according 
to shared structural characteristics such as small size (8-10 kDa), and the presence of 
four cysteine residues in conserved locations that are key to forming their 3-
dimensional shape, functions as a growth regulator and potent chemoattractant for 
neutrophils (45). Members of the chemokine family are divided into two major 
families (CXC or α chemokines, and CC or β chemokines) and two minor families (C 
or γ chemokines, and CX3C or δ chemokine) depending on the spacing of their first 
two cysteine residues. Chemokines promote angiogenesis (the growth of new blood 
vessels), or guide cells to tissues that provide specific signals critical for cellular 
maturation. CXCL1 is a polypeptide hormone of 73 residues with two disulfide bonds 
between C1 and C3, C2 and C4. It plays a role in spinal cord development and is 
involved in biological processes of angiogenesis, inflammation, wound healing and 
tumorigenesis (53, 54). These properties may make CXC family as candidates for in 
vitro evolution to generate specific ligand for target molecules. BDNF receptor, TrkB 
was used as target molecules for directed evolution of CXC random library in present 
study. BDNF and its receptor TrkB mediate neuronal survival, differentiation, 
synaptic plasticity, and neurogenesis (55), show therapeutic potential in the treatment 
of various neurodegenerative diseases, such as Parkinson’ disease (PD), Alzheimer’s 
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disease (AD) and amyotrophic lateral selerosis (ALS) (56-58). However, the 
therapeutic application of BDNF has been greatly limited because of its poor 
permeability blood-brain barrier (BBB). While several completely in vitro display 
systems have recently been used for protein minimization to develop peptide drugs, 
selection of low-molecular-weight BDNF-mimicking peptides with good permeability 
and superior pharmacokinetic properties has met with little success. In order to select 
low-molecular-weight BDNF-mimicking peptides, random cDNA library was 
prepared based on CXCL1 to produce specific ligand to target receptor TrkB by IVC 
selection in emulsion. After construction, in vitro transcription and translation of 
CXCL1 random library, physiological potentials of the library were first investigated 
by biological assay using primary cell culture of hippocampal neurons. Peptide pools 
not only promoted neuronal survival, but also enhanced neurites outgrowth, which 
indicate that CXC-based peptides may mimic cell signaling pathways identical to or 
similar to that of BDNF and/or NGF. Ligand-binding domains (LBD) of target protein 
TrkB which expressed in E.coli had been prepared. The recombinant TrkB had 
binding activity to BDNF, and the value was comparable to previous reports. After 7-
10 rounds selection of CXCL1-based peptides targeting to TrkB, the selected DNA 
pools will be recovered, sequenced, expressed and characterized by proceeding to 
biological assays.  
Present data showed that the peptide pools prepared based on CXC scaffold not 
only significantly promoted neuronal survival, but also enhanced neurite outgrowth. 
The result indicated that the CXC-based peptides may mimic cell signaling pathways 
identical to or similar to that of BDNF and/or NGF, may be of potential application in 
the treatment of various neurodegenerative diseases. The IVC strategy based on 
creating repertoires of microbeads (each displaying a gene and the protein it encodes) 
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were described in present study. Microbead-display libraries can be selected on the 
basis of the binding activity of the displayed polypeptide in the strategy. Present study 
of IVC proceeds well, and can be performed to further study. Further investigation on 
in vitro evolution of CXC random library by using IVC, may help in the development 
of small molecule compounds such as low-molecular-weight BDNF-mimicking 
peptides of potential utility in the treatment of a variety of neurological diseases. 
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